Introduction {#S0001}
============

Acne vulgaris (commonly referred to as acne) is a very common dermatological condition. It is ranked as the eighth most prevalent disease worldwide and affects an estimated 9.4% of the global population.[@CIT0001] Although it mostly affects adolescents,[@CIT0002] acne occurs in patients of all ages, with many individuals experiencing acne during early and even late adulthood.[@CIT0003],[@CIT0004] Acne is far from being a uniquely cosmetic or superficial condition and can have an emotional impact on patients with long-lasting psychosocial effects. Scarring and disfigurement can have a highly detrimental effect on quality of life (QoL) and have an impact on self-esteem, contributing to depression and anxiety.[@CIT0005]--[@CIT0009]

Acne is a chronic inflammatory disorder of the pilosebaceous unit that typically manifests with comedones, papules, pustules, nodules and scars. Androgen-stimulated excess sebum production,[@CIT0010] follicular hyperkeratinization,[@CIT0011] microbial colonization with the Gram-positive anaerobic bacterium *Propionibacterium acnes* (*P. acnes*)[@CIT0011],[@CIT0012] and inflammation[@CIT0013]--[@CIT0015] are key elements involved in the complex pathophysiology of acne. Although the exact underlying mechanisms have not been fully elucidated, an improved understanding of acne pathogenesis[@CIT0016],[@CIT0017] has led to the development of new therapeutic modalities for better disease management. Topical retinoids, benzoyl peroxide (BPO) and systemic antibiotics are currently the first-line treatments for mild-to-moderate acne.[@CIT0018] Although highly effective, topical treatments affect skin barrier integrity and are often associated with side effects such as dryness, irritation, itching and redness. These adverse events are usually temporary and mild. However, they can occasionally be severe or even intolerable, causing a great deal of discomfort to the patient and severely hampering already low levels of compliance with therapy.[@CIT0019],[@CIT0020] These low levels of compliance compromise treatment efficacy and have an impact on clinical outcomes. In addition, antibiotic resistance[@CIT0019] is a growing cause for concern and represents a major obstacle in acne management.

Scientific advances in our understanding of the complex mechanisms driving acne pathophysiology have led to the development of cosmetic products for use as beneficial adjuncts and complementary treatments to modern acne therapy.[@CIT0021]--[@CIT0024] These products improve outcomes by helping to minimize often intolerable side effects, increasing the levels of compliance to treatment,[@CIT0020] supporting treatment in periods of remission, and improving patient QoL.[@CIT0022] In the past few years, only a handful of studies have investigated the effects of cosmetic adjunctive therapy in patients receiving acne treatment.[@CIT0025]--[@CIT0028]

The primary objective of this international observational study was to evaluate, in a real-life setting, the effectiveness of a cosmetic product when it was used as a supportive therapy, alongside conventional topical or systemic anti-acne treatments, by a large population of patients with mild-to-moderate facial acne. The product contained three active ingredients: an antiseborrheic agent, a keratolytic agent and an anti-*P. acnes* agent. It was freely prescribed by the investigator for use over a period of 2 to 3 months. The secondary objectives were to evaluate the effect of the treatment on the severity of the acne, noninflammatory and inflammatory lesions, hyperseborrhea and skin irritation, and on patient QoL. Tolerance to the combined therapy was also investigated.

Subjects And Methods {#S0002}
====================

Study Design And Subjects {#S0002-S2001}
-------------------------

This study was carried out in 11 countries (Belgium, People's Republic of China \[Hong-Kong\], France, Germany, Italy, Mexico, Poland, Portugal, Romania, Russia and Spain), in accordance with applicable regulatory requirements in each country, from March 2015 to November 2016. This was an observational real-life Phase IV study conducted to assess the safety, tolerability and effectiveness of marketed medicines or cosmetics in clinical everyday practice, i.e., in a naturalistic setting where choice of therapy was consistent with approved prescribing information and in line with the usual everyday practice of the physician at his/her office. Other aspects of patient care, including clinical examinations, laboratory investigations, the use of instrumentation, and other invasive and noninvasive procedures were also in consonance with everyday practice. The drug/cosmetic was prescribed by the practitioner him/herself, as per his/her routine practice per label, and there was no systematic assignment of treatment. There was no invasive examination.

In France specifically, when an intervention is "devoid of risks and performed in the framework of usual everyday practice" (research called "research involving the human person Category III"), the law is as follows (Loi Jardé n° 2012-300 of the 5 March 2012, modified by order n° 2016-800 of the 16 June 2016): the patient must be informed and should not be opposed to his/her inclusion in the study and to the collection of data, but a signed informed consent is not necessary. Patients were therefore personally informed of their rights with regard to the processing of their personal data through an information leaflet translated into their native language, in accordance with the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons.

Patients in the age groups 12--18 years, 18--25 years, and those aged 25 years or older, with mild-to-moderate facial acne corresponding to a score of two to three on the investigator's global assessment (IGA) scale[@CIT0029] (i.e., easily recognizable acne involving approximately half of the face, with comedones, papules and pustules, and possibly one nodule), with a minimum of ten noninflammatory and five inflammatory lesions on the whole face (except the nasal pyramid), who were not being treated by systemic isotretinoin and who were prescribed the test product in addition to a medical topical or systemic anti-acne treatment were enrolled in the study. Noninclusion criteria were a known allergy to one or more components of the study product; excessive exposure to sunlight or ultraviolet rays within the previous month; initiation of contraceptive treatment within the past 3 months; clinically and laboratory demonstrated acne related to a clearly hyperandrogenic condition; a cutaneous pathology involving the studied zone with clinical significance and a potentially negative impact on the study results; any chronic systemic disorder or acute pathology that could interfere with the protocol, or the presentation of any condition for which the treatment could interfere with the protocol; and any other condition or treatment which, according to the investigator's judgement, would put the subject at undue risk or may interfere with the evaluation of the study results.

Study Product {#S0002-S2002}
-------------

The study product, designed for acne-prone skin, was a hypoallergenic cosmetic emulsion (Cleanance EXPERT, Eau Thermale Avène, France) with a physiological pH, consisting of patented highly specific anti-acne active ingredients: an antiseborrheic (monolaurin), a keratolytic agent (X-Pressin™) and an agent with anti-inflammatory and anti-*P. acnes* activities (Diolényl^®^, Patent No. WO2010072738A1). Participants were instructed to apply a small quantity of the product in the morning and/or evening, to the entire, freshly cleaned face. In case of a concomitant application of a medical topical anti-acne treatment, the study product had to be applied after complete absorption of the topical drug.

Study Procedure {#S0002-S2003}
---------------

At the inclusion visit, the investigator reviewed any current medical anti-acne treatments and was free to prescribe, or continue to prescribe, the medical anti-acne therapy of their choice in accordance with current guidelines.[@CIT0030] The investigator was also free to provide recommendations (for example on the use of noncomedogenic makeup products, application of sunscreen in case of sun exposure and use of a cleansing product twice a day) according to their usual clinical practice without any specific instructions from the sponsor. Thus, included patients could have had any of the following treatment scenarios: 1) a medical anti-acne treatment initiated; 2) their medical anti-acne treatment unchanged, with only the test cosmetic product added; 3) their medical treatment switched, for example from an antibiotic to BPO﻿; or 4) a new medication added to their ongoing treatment, for example a topical therapy complemented with an oral treatment. Investigators were allowed to enroll a maximum of five patients per center. All participants also received a prescription for the study product as an adjunct treatment to their medical anti-acne therapy. Demographic data, acne history and medical anti-acne treatments at the moment of inclusion were recorded. Skin type and phototype were determined. Epidemiological data on the body sites affected by acne, predominant type of facial acne (noninflammatory, mixed or superficial inflammatory) and presence of secondary lesions (atrophic and hypertrophic scars, and pigmented macules) were also compiled. A follow-up visit was conducted, by the same investigator who carried out the inclusion assessments, after 2 to 3 months of product use (56--84 days). This visit was part of the systematic follow-up of the patient, by the dermatologist usually responsible for their management. No constraints were associated with this study and no additional invasive or specific examinations were carried out.

Clinical Evaluations {#S0002-S2004}
--------------------

### Primary Effectiveness Criterion {#S0002-S2004-S3001}

The global effectiveness of the medical anti-acne treatments in combination with the cosmetic product was evaluated by measuring changes in facial acne at follow-up compared to inclusion according to a 6-point scale: 1: total disappearance of acne; 2: large improvement; 3: moderate improvement; 4: slight improvement; 5: no change; 6: aggravation. Given the large size of the cohort and the real-life setting used in this study, this scale was developed to allow direct evaluation of any overall changes in facial acne during the study period.

### Secondary Effectiveness Criteria {#S0002-S2004-S3002}

The severity of facial acne was quantified at inclusion and at follow-up using the IGA scale[@CIT0029] from 0 (clear), 1 (almost clear), 2 (light), 3 (moderate) to 4 (severe) and the percentage change in the IGA score was calculated. A decrease in the score indicated improvement.

The severity of objective clinical symptoms -- such as noninflammatory and inflammatory lesions, hyperseborrhea and skin irritation -- was graded by the physician at inclusion and follow-up using a 4-point scale from 0 (absent) to 3 (severe). The percentage change in the score was calculated between inclusion and follow-up. A decrease indicated improvement.

The impact of the skin condition on patient QoL was measured at inclusion and follow-up using the Cardiff acne disability index (CADI)[@CIT0031] patient questionnaire. Each answer was scored using a 4-point scale of decreasing severity from 3 (severe disability) to 0 (absence of disability). The overall CADI score was calculated by summing the score of each answer and ranged from 0 to 15. The higher the score, the more QoL was impaired.

### Tolerance {#S0002-S2004-S3003}

Clinical tolerance was assessed by the dermatologist and the patient at follow-up using a 4-point scale ([Table 1](#T0001){ref-type="table"}). Adverse events and serious adverse events were reported and documented throughout the study.Table 1Tolerance Evaluation ScaleScoreDefinitionDescription0PoorFunctional and/or objective symptoms that lead to discontinuation of product use1ModeratePronounced or persistent functional discomfort symptoms or objective symptoms that do not lead to discontinuation of product use2GoodMild transient functional symptoms that do not lead to discontinuation of product use and no objective symptoms upon examination3Very goodNo functional discomfort symptoms and no objective symptoms upon examination

Statistical Analysis {#S0002-S2005}
--------------------

All analyses were carried out using SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA). Analyses were conducted on data from three patient populations or subpopulations: all patients for whom epidemiological data were available (whole study population), patients for whom inclusion and follow-up visit data were available (per protocol \[PP\] population), and patients whose medical anti-acne treatment had not been changed at the inclusion visit (subpopulation analysis). Epidemiological, demographic and acne characteristics at inclusion were analyzed for the whole population, tolerance was analyzed using data from the PP population, and the primary and secondary efficacy outcomes were analyzed using data from the PP population and the subpopulation. Indeed, due to the observational design of the study, the subpopulation of patients whose medical anti-acne treatment remained unchanged at inclusion was the only group in which the specific effectiveness of the cosmetic product could be evaluated by before-and-after intragroup comparisons. Missing data were not replaced and were treated as such in the statistical analysis. The numbers and percentages of patients were calculated for all variables. Quantitative variables were expressed as the mean±standard deviation. Median, min--max values and 95% CIs were calculated when appropriate. Differences in severity scores between inclusion and follow-up, and percentage changes were analyzed using the Wilcoxon matched-pairs signed-rank test. A paired Student's *t*-test was used for CADI scores. Statistical significance was set at p\<0.05.

Results {#S0003}
=======

Baseline Demographics And Clinical Characteristics {#S0003-S2001}
--------------------------------------------------

Participant flow through the study is shown in [Figure 1](#F0001){ref-type="fig"}. A total of 3960 patients were included in the study. Epidemiological data were available for 3955 of these patients and 3746 patients were included in the PP population. In the whole study population, 1966 patients (50.9%) had their medical anti-acne treatment initiated at inclusion, 891 patients (23.1%) had their medical treatment left unchanged at inclusion, 628 patients (16.2%) were switched to another treatment and 380 patients (9.8%) had another drug added to their treatment. Thirty-two of the patients whose medical anti-acne treatment remained unchanged at inclusion were lost to follow-up; the remaining 859 patients formed the subpopulation.Figure 1Participant flow through the study.

The average duration between visits was 61.7 days. The demographic and clinical characteristics of the whole study population are shown in [Tables 2](#T0002){ref-type="table"} and [3](#T0003){ref-type="table"}, respectively.Table 2Demographics And Skin Characteristics At Inclusion In The Whole Study PopulationParameterWhole Study Population At Inclusion (N=3955)**Gender, n (%)**N=3919Male1337 (34.1)Female2582 (65.9)**Age, years**N=3922Mean±SD18.4 ± 4.1Median (min--max)18 (11--49)**Age groups, n (%)**N=395512--18 years1905 (48.2)18--25 years1707 (43.2)≥25 years343 (8.7)**Skin characteristics, n (%)^a^**N=3680Mixed2437 (66.2)Dry156 (4.2)Oily1087 (29.5)**Skin phototype, n (%)^b^**N= 3575I99 (2.8)II1324 (37.0)III1705 (47.7)IV396 (11.1)V36 (1.0)VI15 (0.4)[^1] Table 3Acne History And Clinical Characteristics At Inclusion In The Whole Study PopulationParameterWhole Study Population (N=3955)**Family history of acne, n (%)**Yes1124 (29.2)**Duration of acne prior to inclusion, years**Mean±SD3.3±3.3Median (min--max)2 (0--28)**Facial acne, n (%)** **Sites affected**Forehead3009 (76.6)Cheeks2863 (72.9)Mandibular region2000 (50.9) **Type of facial acne**Mixed2395 (61.6)Noninflammatory668 (17.2)Superficial inflammatory826 (21.2) **Secondary lesions**Presence of lesions1641 (42.4)Atrophic scars720 (47.4)Hypertrophic scars103 (6.8)Hyperpigmented spots1028 (67.3)**Other body sites affected by acne, n (%)**Back1254 (35.2)Neck285 (8.1)Shoulders754 (21.2)Chest683 (19.2)**History of acne treatment prior to inclusion, n (%)**Yes2704 (70.2)**Number of acne treatments prior to inclusion**N=2704Mean±SD2.3±1.3Median (min--max)2 (1--9)**Type of prescription at inclusion, n (%)**Addition to an ongoing treatment380 (9.8)Initiation of treatment1966 (50.9)Switched treatment628 (16.2)Unchanged treatment891 (23.1)**Acne treatment at inclusion^a^, n (%)** **Topical**Retinoids763 (20.2)BPO646 (17.1)Fixed combination retinoids+BPO643 (17.0) **Systemic**Zinc547 (13.8)Doxycycline671 (17.7)[^2]

At inclusion, 89.1% (n=756) of the subpopulation of patients whose medical anti-acne treatment was left unchanged and 89.4% (n=3296) of the PP population had mild-to-moderate acne ([Figure 2](#F0002){ref-type="fig"}). There were no differences in the severity of facial acne, as indicated by the IGA scores, or in objective clinical symptoms between the two populations at inclusion ([Table 4](#T0004){ref-type="table"}).Table 4Acne Investigator's Global Assessment And Objective Clinical Symptom Severity Scores In The Per Protocol Population And In The Subpopulation Of Patients Whose Medical Anti-Acne Treatment Remained Unchanged At InclusionSeverity Scores Mean±SDPP Population (N=3746)Patients Whose Treatment Remained Unchanged (N=859)InclusionFollow-Up% ChangeInclusionFollow-Up% ChangeIGA2.36±0.681.46±0.78−37.4 \*\*\*\*2.33±0.671.44±0.80−38.3 \*\*\*\*Noninflammatory lesions1.55±0.650.93±0.59−35.7\*\*\*\*1.54±0.640.93±0.63−35.3\*\*\*\*Superficial inflammatory lesions1.54±0.670.73±0.61−50.0\*\*\*\*1.50±0.650.74±0.62−47.0\*\*\*\*Hyperseborrhea1.42±0.720.72±0.62−43.8\*\*\*\*1.38±0.720.75±0.64−40.6\*\*\*\*Skin irritation0.75±0.770.32±0.54−35.1\*\*\*\*0.76±0.750.29±0.53−37.2\*\*\*\*[^3][^4] Figure 2Severity of facial acne at inclusion and at follow-up after 2--3 months of use of the cosmetic product in combination with medical anti-acne therapy in the per protocol (PP) population (N=3746) and in the subpopulation of patients whose medical anti-acne treatment remained unchanged at inclusion (N=859). Severity was graded by the physician using the acne investigator's global assessment (IGA) scale from 0 (clear) to 4 (severe). The percentages of patients with each score are shown.

Effectiveness Evaluations {#S0003-S2002}
-------------------------

The results of the effectiveness analyses carried out on the PP population and those carried out on the subpopulation of patients whose medical anti-acne treatment remained unchanged at inclusion are presented in [Figures 2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"}, and in [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}. However, as the results obtained for the PP population for all evaluation criteria were similar to those obtained for the subpopulation, only the results for the subpopulation are described in this section.Table 5Global Cardiff Acne Disability Index (CADI) Score And CADI Score Category At Inclusion And At The End Of Treatment In The Per Protocol Population And In The Subpopulation Of Patients Whose Medical Anti-Acne Treatment Remained Unchanged At InclusionGlobal CADI ScoreInclusionFollow-Up**PP population** (N=3746)Mean±SD5.0 ± 3.02.7 ± 2.4Median (min--max)5.0 (0--15.0)2.0 (0--13.0)% change−39.4\*\*\*\***Patients with treatment unchanged** (N=859)Mean±SD5.1±3.02.7±2.2Median (min--max)5.0 (0--15.0)3.0 (0--12.0)% change−38.3\*\*\*\***CADI score category**, n (%) \[95% CI\]0: Quality of life not affected by acne186 (5.0)\
\[4.3; 5.7\]829 (22.2)\
\[20.9; 23.5\]1: Quality of life slightly affected by acne2137 (57.1)\
\[55.5; 58.7\]2485 (66.5)\
\[64.9; 68.0\]2: Quality of life moderately affected by acne1258 (33.6)\
\[32.1; 35.2\]407 (10.9)\
\[9.9; 11.9\]3: Quality of life severely affected by acne159 (4.2)\
\[3.7; 5.0\]17 (0.4)\
\[0.3; 0.7\][^5][^6] Figure 3Global effectiveness at follow-up after 2--3 months of use of the cosmetic product in combination with medical anti-acne therapy in the per protocol (PP) population (N=3746) and in the subpopulation of patients whose medical anti-acne treatment remained unchanged at inclusion (N=859). Global effectiveness was measured by the physician with a 6-point scale from 1 (total disappearance) to 6 (aggravation). The percentages of patients with each score are shown.

### Primary Efficacy Criterion {#S0003-S2002-S3001}

At the end of treatment, a large or moderate improvement of facial acne was recorded for 76.6% (n=653) of the patients whose medical anti-acne treatment remained unchanged at inclusion. Acne had totally disappeared in 7.9% (n=67) of these patients ([Figure 3](#F0003){ref-type="fig"}).

### Secondary Efficacy Criteria {#S0003-S2002-S3002}

#### Severity Of Facial Acne {#S0003-S2002-S3002-S4001}

In the group whose medical treatment remained unchanged, the number of patients cleared and almost cleared of facial acne markedly increased from 9.0% (n=77) at inclusion to 52.8% (n=447) at the end of the 2- to 3-month study period, whereas the number of patients with moderate acne profoundly decreased from 38.9% (n=330) to 7.0% (n=59) ([Figure 2](#F0002){ref-type="fig"}). The mean severity of acne also significantly improved, as shown by a 38.3% decrease in the average IGA score (difference in score: −0.90±0.75, p\<0.0001) ([Table 4](#T0004){ref-type="table"}).

#### Noninflammatory And Superficial Inflammatory Lesions {#S0003-S2002-S3002-S4002}

A 35.3% and 47.0% reduction in the severity score for noninflammatory and inflammatory lesions, respectively, was recorded between inclusion and the end of the study period in the patients whose medical anti-acne treatment remained unchanged (differences in score: −0.61±0.69, p\<0.0001 and −0.76±0.69, p\<0.0001, respectively) ([Table 4](#T0004){ref-type="table"}).

#### Hyperseborrhea {#S0003-S2002-S3002-S4003}

A 40.6% reduction in the severity score for hyperseborrhea was recorded between inclusion and the end of the study period in the patients whose medical anti-acne treatment remained unchanged (difference in score: −0.64±0.69, p\<0.0001) ([Table 4](#T0004){ref-type="table"}).

#### Skin Irritation {#S0003-S2002-S3002-S4004}

A 37.2% decrease in the severity score for skin irritation was found between inclusion and the end of the study period in the patients whose medical treatment remained unchanged (difference in score: −0.46±0.72, p\<0.0001) ([Table 4](#T0004){ref-type="table"}).

### Quality Of Life {#S0003-S2002-S3003}

An improvement in QoL, as shown by the 38.3% reduction in the global CADI score (difference in score: −2.32±2.68, p\<0.0001), was recorded between inclusion and the end of the study period in the patients whose medical anti-acne treatment remained unchanged ([Table 5](#T0005){ref-type="table"}).

### Tolerance {#S0003-S2002-S3004}

Tolerance to the combined medical anti-acne and cosmetic treatment, rated by the clinicians and the patients themselves, was good to very good in around 95% (n=3533 or n=3470, respectively) of the PP population, regardless of the medical anti-acne therapy being taken. Overall, 77% (n=2750) of the PP population considered that the test product had helped them to cope with their acne treatment and 89.8% (n=3257) wished to continue using it after the end of the study. Adverse events were reported by only 2.3% (n=83) of patients (95% CI \[1.82; 2.80\]).

Discussion {#S0004}
==========

In this international, observational, real-life study, the use of an adjunct cosmetic product for 2--3 months in association with conventional medical anti-acne therapy significantly improved the appearance and severity of mild-to-moderate acne. This combined therapy was globally very efficient. Moderate-to-large improvements in facial acne were observed in over 75% of the patients, and five times fewer patients were classed as having moderate acne by the end of the study period, both in the subpopulation of patients whose medical anti-acne treatment remained unchanged at inclusion and in the PP population. The combined treatment also led to a reduction in the number of noninflammatory and inflammatory lesions, hyperseborrhea and skin irritation. The product also led to improved patient QoL and was very well tolerated.

The predominance of females, the mean patient age of 18.4 years and the overall acne prevalence of 91.4% in patients aged between 12 and 24 years recorded in our population were in accordance with epidemiological data from previous studies.[@CIT0002],[@CIT0032] Less than 30% of our study population had a family history of acne, which is lower than the 62--75% reported in other studies.[@CIT0033],[@CIT0034] The treatments prescribed to the patients included in our study were mainly recommended first-line treatments for mild-to-moderate acne: topical retinoids, BPO, fixed combination retinoids and BPO, and systemic antibiotics.[@CIT0018],[@CIT0035] Some patients received oral zinc therapy, which has been widely used in the management of acne for decades.[@CIT0036]

Although our study was centered around patients with mild-to-moderate acne at inclusion, we reported a highly significant improvement in the severity of acne in the PP population, with a 37.4% reduction in the IGA score. A similar and highly significant 38.3% decrease in the IGA score was observed in the subpopulation of patients who were already taking an anti-acne treatment that was not changed at inclusion. These results indicate that the improvements in acne severity in the PP population were not solely due to initiation or changes in the medical anti-acne therapy and that the effectiveness of the prescribed anti-acne regimens improved when they were used in combination with the adjunct cosmetic product. Similarly, the combined treatment led to highly significant improvements in the severity of noninflammatory and superficial inflammatory lesions, hyperseborrhea and skin irritation. The extent of improvement in these objective clinical symptoms was similar in the PP population and in the subpopulation of patients whose acne treatment remained unchanged at inclusion. These findings demonstrate that the adjunct cosmetic product was also effective at improving these objective clinical parameters.

Retinoids and BPO were prescribed at inclusion for some of the patients in our study. These treatments are often used in combination to combat the multiple pathogenic mechanisms that can be involved in the development of acne and therefore increase the likelihood of successful acne therapy; however, this combined therapy is often associated with an increased risk of side effects. Our cosmetic product contained active ingredients with antiseborrheic, keratolytic and anti-*P. acnes* properties. Our results suggest that the components of this product, when used in a complementary treatment together with conventional anti-acne therapies, might be highly beneficial for the global management of mild-to-moderate lesions. The benefits of this product can most likely be attributed to the complementary and/or synergistic mechanisms of action of the active ingredients, which effectively target excess production of sebum, follicular hyperkeratinization and microbial colonization with *P. acnes*, and enhance the tolerability of topical regimens.

In the present study, patients reported that acne had a moderate impact on their QoL at inclusion, with an average global CADI score of around five. Previous studies of patients with acne of similar severity to that noted in our study reported a markedly more impaired QoL, with CADI scores of seven, eight or above.[@CIT0008],[@CIT0022] Despite the moderate impact of acne on patient QoL in our study, we observed a highly significant improvement in QoL by the end of the study period. This improvement was observed both in the subpopulation of patients whose medical anti-acne treatment remained unchanged and in the PP population, with highly significant reductions in global CADI scores of more than one-third. These findings further confirm the effectiveness of the combined treatment.

Both the clinician and patient evaluations indicated that tolerance to the combined therapy after 2--3 months of use was very good, and most patients wished to continue using the cosmetic product after the end of the study. Levels of satisfaction among patients with acne are an important issue given the substantial psychosocial impact of acne: positive emotional reactions may contribute to increased treatment adherence and more successful clinical outcomes.

The strength of our study was its noninterventional nature, which allowed a large international cohort of patients from 11 countries to be observed in a real-life setting over an extended time period. Each participating dermatologist was at liberty to prescribe the acne therapy of their choice without any recommendations from the sponsor, and patients followed their treatment plan using the product under everyday conditions. Although our conditions differed from those of a controlled clinical trial, during which patients often feel more compelled to adhere to their treatment and have a positive perception of the study, our study clearly demonstrated the global effectiveness of combining supportive treatment with the cosmetic product with conventional anti-acne therapy. However, the absence of any compliance assessments may be a potential limitation of this real-life study design. Indeed, use of the cosmetic product may well have had an impact on compliance to conventional anti-acne regimens, with the reported effectiveness likely resulting from a combination of the direct action of the active ingredients and increased adherence to the medical anti-acne regimen as use of the product alleviated the side effects and the conventional medications became more tolerable. As this was an observational study, it was not possible to include a control group receiving a placebo in addition to the anti-acne therapy. As an alternative, we used a before-and-after design to evaluate the effectiveness of the study product in the subpopulation of patients whose medical anti-acne treatment remained unchanged at inclusion, allowing each patient to serve as their own control.

In conclusion, this international observational study demonstrated the benefits of using the cosmetic skin care product, Cleanance EXPERT, as an adjuvant care modality to improve clinical outcomes and minimize the harmful side effects of conventional treatment regimens for mild-to-moderate acne. Tolerance to the combined therapy was very good, regardless of the prescribed anti-acne regimen. This good level of tolerance had a positive impact on patient QoL, which could, in turn, lead to increases in patient satisfaction, treatment adherence and levels of therapeutic success.
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[^1]: **Notes:** ^a^Skin characteristics were described according to the investigator's clinical evaluation. ^b^Skin phototypes were defined according to the Fitzpatrick scale.

[^2]: **Notes:** ^a^Treatments prescribed to more than 10% of patients.

    **Abbreviation:** BPO, benzoyl peroxide.

[^3]: **Notes:** \*\*\*\*P\<0.0001 for the difference in severity scores between follow-up at the end of the 2--3 months of treatment and inclusion. Analyses were conducted using the Wilcoxon matched-pairs signed-rank test.

[^4]: **Abbreviations:** PP, per protocol; IGA, investigator's global assessment.

[^5]: **Notes:** \*\*\*\*P\<0.0001 for the difference in global CADI score between follow-up at the end of the 2--3 months of treatment and inclusion. Analyses were carried out using the Student's *t*-test.

[^6]: **Abbreviation:** CADI, Cardiff acne disability index.
